The prophylactic effect of continuously infused landiolol started just before the end of surgery against tachycardia during tracheal extubatio

Phase 4

• Conditions: Patients undergoing a surgery with general anesthesia

• Registration Number: JPRN-UMIN000004648
• Lead Sponsor: Bellland General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-01
• Study Completion: 2011-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

patients with chronic heart failure, atrio-ventricular block, sick-sinus syndrome, diabetic ketoacidosis, hypothyroidism, WPW syndrome, hypotention (systric and diastric blood pressure should be more than 90 and 60, respectively), bradycardia (HR < 50), recieved nicardipine treatment for hypertention with extubation, asthma, with beta-blocker treatment, with anaphylaxis for flurbiprofen, with pregnancy, with anaphylaxis for landiolol, judged as unsuitable for this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the maximum heart rate during tracheal extubation

Secondary Outcome Measures

Name	Time	Method
age, height, body weight, sex, preoperative complications blood pressure and heart rate (at starting infusion of landiolol, 10 min after starting infusion of landiolol, maximum heart rate during tracheal extubation, after tracheal extubation, at discharging the patient from operating room) operative time, anesthetic time, total fluid infusion, total operative bleeding, total volume of urine, total transfusion total dose of fentanyl, total dose of remifentanil, total dose of landiolol the incidence of side effect (bradycardia etc.)